Preliminary Schedule (subject to change)

Hover over each speaker's name to read a brief bio

8:30 a.m. – 12:30 p.m.
Industry Wednesday Symposia and Focus Sessions
1:00 – 3:20 p.m.
Plenary I - Presidential Symposium

Welcome Remarks: Allen Eaves, President and CEO, STEMCELL Technologies

President's Address

Presentation of the McEwen Award for Innovation to Azim Surani

Presentation of the ISSCR Public Service Award to Paolo Bianco, Elena Cattaneo, and Michele De Luca

Gordon Keller, McEwen Centre for Regenerative Medicine, Ontario Cancer Institute, Canada

Brigid Hogan, Duke University Medical Center, USA

Olivier Pourquie, IGBMC,Strasbourg University Medical School, France

Lorenz Studer, Sloan Kettering Institute for Cancer Research, USA

3:20 – 4:00 p.m.
Refreshment Break
4:00 - 6:25 p.m.
Plenary II - Cell Heterogeneity

John Dick, Princess Margaret Cancer Centre, University Health Network, Canada

Kateri Moore, Mount Sinai School of Medicine, USA

Alexander van Oudenaarden, Hubrecht Institute, Netherlands

     5 Poster Teasers

ISSCR Business Meeting

Connie Eaves
, Terry Fox Lab, BC Cancer Agency, Canada

6:30 – 8:30 p.m.
Poster Presentation I, Opening Reception
8:00 – 8:30 a.m.
Innovation Showcases
West Ballroom A
STEMCELL Technologies
West Ballroom B
R&D Systems
West Ballroom C/D

West Meeting Room 211-214
Union Biometrica
West Meeting Room 301-305
9:00 – 11:20 a.m.
Plenary III – Therapies in the Clinic

Leigh Turner, University of Minnesota, USA

A.M. James Shapiro, University of Alberta, Canada

Roger Barker, Cambridge Center for Brain Repair, UK

Patient Advocate Address
Jennifer Molson

Luigi Naldini, San Raffaele-Telethon Institute for Gene Therapy, Italy

Michel Sadelain, Memorial Sloan-Kettering Cancer Center, USA

11:20 a.m. – 1:15 p.m.
Lunch Break
11:30 a.m. – 1:00 p.m.
Junior Investigator Events:
Meet the Experts Networking Lunch

11:30 - 12:30 p.m.
Innovation Showcases
West Ballroom A
STEMCELL Technologies
West Ballroom B
West Ballroom C/D
BD Biosciences
West Meeting Room 211-214
West Meeting Room 301-305
Life Technologies
1:15 – 3:05 p.m.
Concurrent Session I (5 Tracks)
A Neural Stem Cells and Development
Supported by StemCells, Inc.

Freda Miller
Hospital for Sick Children, Canada

Arnold Kriegstein
UC San Francisco, USA

B Control of Pluripotency
Supported by Stemgent

Shinya Yamanaka
Center for iPS Cell Research and Application (CiRA), Japan

Manuel Serrano
Spanish National Cancer Research Centre, Spain

C Road to the Clinic:
Challenges Ahead

Alan Trounson California Institute for Regenerative Medicine, USA

Christopher K. Breuer
Nationwide Children's Hospital, USA

D Regeneration Supported by Ontario Brain InstituteMichael Rudnicki
Ottawa Hospital Research Institute, Canada
E Aging and Metabolism

Kirsty Spalding
Karolinska Institutet, Sweden

Heinrich Jasper
The Buck Institute for Research on Aging, USA

3:05 – 4:00 p.m.
Refreshment Break
4:00 – 5:50 p.m.
Concurrent Session II (5 Tracks)
A Neural Differentiation
Supported by Lieber Institute for Brain Development

Sally Temple
Neural Stem Cell Institute, USA

Ronald McKay
Lieber Institute for Brain Development, USA

B Trans-

Melissa Little
University of Queensland, Australia

Lijian Hui 

Shanghai Institute of Bioligical Sciences, CAS, China


C Cancer Plasticity

Speaker TBD

Luis Parada

U. Texas Southwestern Medical School, USA

D Epithelial & Mesenchymal Stem Cells

Nick Barker
Institute of Medical Biology, Singapore

Bruce Edgar
University of Heidelberg, Germany

E Model Organisms

Hannele Ruohola-Baker
University of Washington, USA

Nadia Mercader
Centro Nacional de Investigaciones Cardiovasculares, Spain

6:00 – 8:00 p.m.
Poster Presentation II, Reception
8:00 – 8:30 a.m.
Innovation Showcases
West Ballroom A
STEMCELL Technologies
West Ballroom B
Miltenyi Biotec
West Ballroom C/D
West Meeting Room 211-214
West Meeting Room 301-305
9:00 – 11:20 a.m.
Plenary IV – Bioengineering

Anthony Atala, Wake Forest University, USA

Jason A. Burdick, University of Pennsylvania, USA

Molly Stevens, Imperial College, London, UK

Peter Zandstra, University of Toronto, Canada

Robin Lovell-Badge
, Medical Research Council, National Institute for Medical Research, UK

11:20 a.m. – 1:15 p.m.
Lunch Break
11:30 a.m. – 1:00 p.m.
Junior Investigator Events:
Meet the Experts Networking Lunch

11:30 - 12:30 p.m.
Innovation Showcases
West Ballroom A
Biological Industries
West Ballroom B
West Ballroom C/D
EMD Millipore
West Meeting Room 211-214
Irvine Scientific
West Meeting Room 301-305
1:15 – 3:05 p.m.
Concurrent Session III (5 Tracks)
A Sensory Systems Repair

Steven D. Schwartz
Jules Stein Eye Institute, USA

Albert Edge
Harvard Medical School, USA

B Modeling Disease with iPSCs
Supported by Cellular Dynamics International

Fred H. Gage
Salk Institute for Biological Sciences, USA

Christine Mummery
Leiden University Medical Center, Netherlands

C Diabetes
Supported by Sanofi

M. Cristina Nostro
McEwen Centre for Regenerative Medicine, Canada

Maike Sander
UC San Diego, USA

D Epigenetics

Laurie Boyer
Massachusetts Institute of Technology, USA

Andres Nagy
Mount Sinai Hospital, Canada

E Asymmetric Cell Division

Roeland Nusse
Howard Hughes Medical Institute, Stanford University, USA

Rong Li
Stowers Institute for Medical Research, USA

3:05 – 4:00 p.m.
Refreshment Break
4:00 – 5:50 p.m.
Concurrent Session IV (5 Tracks)
A Monitoring and Modulating the Niche

Melody Swartz
EPFL, Switzerland

Dennis Discher
University of Pennsylvania, USA

B Large Scale Analysis of Cell Fate Decisions

Bruno Reversade
Institute for Medical Biology, Singapore

C Stem Cells and Cancer

Catriona Jamieson
Moores Cancer Center, UC, San Diego, USA

Qing Li
University of Michigan, USA

D Hematopoiesis
Supported by The Hospital for Sick Children

Stuart Orkin
Boston Children's Hospital, Dana Farber Cancer Institute, USA

Michael Sieweke
CIML, France

E Germline Biology

Amander Clark

Hiroyuki Sasaki
Kyushu University, Medical Institute of Bioregulation, Japan

6:00 – 8:00 p.m.
Poster Presentation III, Reception
8:00 – 8:30 a.m.
Innovation Showcases
West Ballroom A
LifeMap Sciences Inc.
West Ballroom B
EMD Millipore
9:00 – 11:25 a.m.
Plenary V – Inflammation and Tissue Repair

Ajay Chawla, University of California, San Francisco, USA

Florian Greten, Georg-Speyer-Haus, Germany

Frederic Geissmann, King's College London, UK

Nicolas Buchon, Cornell University, USA

ISSCR-BD Biosciences Outstanding Young Investigator Award Lecture

11:20 a.m. – 1:15 p.m.
Lunch Break
11:25 a.m. – 1:00 p.m.
Junior Investigator Events:
Career Panel

11:30 - 12:30 p.m.
Innovation Showcases

1:15 – 3:00 p.m.
Plenary VI – Mesenchymal Stromal Cells

Paolo Bianco, Sapienza University of Rome, Italy,

Yufang Shi, Institute of Health Sciences, SIBS, China

Simon Mendez-Ferrer, National Center for Cardiovascular Research, Madrid, Spain

T. Michael Underhill, University of British Columbia, Canada

3:00 – 3:40 pm
Refreshment Break
3:40 – 6:00 p.m.
Plenary VII – Epigenetics and Pluripotency

President-Elect Address

Kathrin Plath, UCLA School of Medicine, USA

Guo-liang Xu, Institute of Biochemistry & Cell Biology, Chinese Academy of Sciences, Shanghai, China

Hongkui Deng, Peking University, China

Keynote Address
Susan L. Lindquist
, Whitehead Institute for Biomedical Research

Closing Remarks

6:00 – 7:00 p.m.
Closing Reception
AtalaDr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. His current work focuses on growing new human cells, tissue and organs. Ten applications of technologies developed in Dr. Atala's laboratory have been used clinically. View Dr. Atala's online profile for more information.
BiancoDr. Bianco's work focuses on stem cells for skeletal tissues in the bone marrow, aka mesenchymal stem cells, their biology, role in disease and significance in therapies and medicine. His contributions include the direct identification of such cells in the human bone marrow, prospective isolation, identity as perisinusoidal cells, role in the hematopoietic niche and proof of their self-renewal in vivo.
Dr. Breuer runs a NIH funded laboratory that focuses on cardiovascular tissue engineering. Dr Breuer is the principal investigator on the first FDA-approved study evaluating the use of tissue engineered vascular grafts in humans. This study is evaluating the safety and growth potential of tissue engineered vascular graft in congenital heart surgery. View Dr. Breuer's online profile for more information.
Dr. Eaves received her PhD in Immunology from the University of Manchester in the UK. She continued her post-doctoral training in experimental hematology at the Ontario Cancer Institute. Dr. Eaves and her husband co-founded the Terry Fox Laboratory in 1981, at the BC Cancer Agency and together built an internationally recognized research program in normal and cancer stem cell biology, leukemia and bone marrow transplantation. For more information, visit the Terry Fox website.
Dr. Gilbertson’s laboratory research is focused on understanding the link between normal development and the origins of cancer, particularly brain tumors. His lab was the first to describe a cancer stem cell niche in brain tumors; demonstrate that a solid cancer can arise from tissue specific stem cells; use innovative cross-species genomics to trace the developmental origins of pediatric brain tumors; and to use whole genome sequencing to identify novel subgroup-specific mutations in medulloblastoma. His research has been translated into numerous diagnostic tests and innovative clinical trials for children with cancer. Visit Dr. Gilbertson’s online profile at the St. Jude Children’s Research Hospital website for more information
Dr. Hu's current research is focused on the molecular mechanisms of differentiation regulation of liver stem cells, and on direct transdifferentiation of fibroblasts into hepatic stem cells.
Dr. Jamieson has a broad background in molecular stem cell biology and immunology, with specific training and expertise in key areas of stem cell research. Her research demonstrated that what is causing the self-renewal of cancerous cells in blast crisis CML is driven, at least in part, by mistakes in certain regulatory genes. This led to discovery of molecules to correct those gene pathways that are now being tested in two different Phase 1 clinical trials for two different blood cancers. A successful, recently completed Phase l JAK2 inhibitor clinical trial, showed promising results for mylofibrosis. Visit the Jamieson Lab online for more information
Dr. Jasper’s studies focus on the role of stress signaling in regulating various aspects of physiology that influence lifespan in Drosophila. Most recently, his lab has initiated studies to characterize the role of stem cells and proliferative homeostasis in maintaining the health and lifespan of flies, establishing newly identified regenerative processes in the Drosophila midgut as a model for understanding the importance of somatic stem cell function for the lifespan of metazoans.Visit the Jasper Lab online for more information
Dr. Lindquist has shown that forces governing protein folding have a profound and unexpected impact on evolution and human disease. Further, her work on the heat shock protein Hsp90 changed paradigms in evolutionary biology, showing that Hsp90 buffers naturally occurring variation allowing it to accumulate in a silent state and releasing it in times of stress. For more information, visit the Lindquist Lab website.
Dr. Melissa Little’s research focuses on the molecular basis of kidney development, renal disease and repair. She is internationally recognized both for her work on the systems biology of kidney development and also for her pioneering studies into potential regenerative therapies in the kidney. This work has encompassed the characterization of adult stem cells in the kidney as well as analyses of the embryonic progenitor population. Visit Dr. Little's lab webpage for more information.
Dr. Miller is best known for her studies of neural and dermal stem cells and of neuronal growth, survival and apoptosis. Major findings from her lab have provided evidence that adult mammalian skin contains an accessible multipotent dermal stem cell that can generate peripheral neural cells, that the p75 and p63 play a critical role in determining the life, death and degeneration of mammalian neurons, and that one way genetic disorders cause cognitive dysfunction is by perturbing embryonic neurogenesis. Visit Dr Miller’s online profile for more information
Dr. Mummery’s research concerns heart development and the differentiation of pluripotent human stem cells into the cardiac and vascular lineages and using these cells as disease models, for safety pharmacology, drug discovery and future cardiac repair. Learn more about Dr. Mummery and her research by visiting her online profile.
Dr. Barker identified the Wnt target gene Lgr5 as a unique marker of adult stem cell populations in various organs, including the intestine, skin and stomach. This work also led to the discovery that the intestinal Lgr5 stem cells are the cell-of-origin of colon cancer and revealed Lgr5 as a candidate marker of cancer stem cell populations. He continues to focus on the role of Lgr5 adult stem cells in epithelial renewal and cancer in organs including stomach and ovary. Find out more by visiting Dr Barker’s online profile.
For the last 19 years, Luigi Naldini has pioneered the development and applications of lentiviral vectors for gene transfer, which have become one of the most widely used tool in biomedical research and, upon recently entering clinical testing, are providing a long sought hope of cure for several currently untreatable and otherwise deadly human diseases. Learn more about Dr Naldini’s research by visiting his online profile.
Dr. Pourquié’s laboratory recently developed optimized protocols allowing the efficient production of skeletal muscle and vertebral precursors in vitro from embryonic stem cells by recapitulating stepwise early differentiation of the paraxial mesoderm in vivo. These results represent a key first step toward establishing novel differentiation protocols for skeletal, muscular and other clinically relevant tissues to analyze developmental and pathological processes in human cells or to serve as the basis for future cell based therapies.
keller1Dr. Keller is best known for his breakthrough success to differentiate human embryonic stem (ES) cells into cardiac lineages. His current research aims to elucidate a better understanding of the mechanisms that control mesoderm and endoderm induction and specification in mouse and human embryonic stem (ES) cell cultures. His studies focus specifically on the generation of the following derivative lineages: hematopoietic, vascular, cardiac, hepatic and pancreatic. Read more about Dr Keller by visiting his online profile.
studer1Dr Studer’s lab pioneered strategies for the directed differentiation of pluripotent stem cells. He also developed some of the first iPS cell-based disease models and is currently leading a large effort towards the clinical application of human pluripotent stem cells in Parkinson's disease. Learn more by visiting Dr. Studer’s lab online.
Dr. Buchon’s research interest is to understand the genetic and cellular mechanisms that maintain intestinal homeostasis in response to indigenous and pathogenic microbes. In previous work, he revealed that microbiota and pathogenic bacteria affect both intestinal stem cell proliferation and their subsequent lineage using Drosophila melanogaster as a model system. Visit the Buchon Lab’s website for more information.
Dr. Gage's work concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. In addition, he models human neurological and psychiatric disease in vitro using human stem cells. Finally, his lab studies the genomic mosaicism that exists in the brain as a result of mobile elements that are active during neurogenesis. Read more about Dr Gages research.
Dr. Dick's research has revolutionized the study of normal and leukemic human stem cells by developing a system for transplanting normal and malignant human hematopoietic cells into immune-deficient mice; and by using this method to identify and characterize both normal and leukemic human stem cells. His lab established that only a small proportion of human leukemic cells were capable of initiating human leukemia within the immune-deficient mice. Purifiying these leukemia-initiating cells provided direct evidence for the cancer stem cell hypothesis. Through his work, he has pioneered the field of cancer stem cell biology, transformed our views of the origin and nature of cancer, and laid the foundation for new approaches to cancer therapy. Visit Dr John Dick’s Lab online for more information
Dr. Kateri Moore moved to Mount Sinai in 2007, where she has continued to develop her studies of hematopoietic stem cells and their niche interactions and to expand into research that involves the direct reprogramming of somatic cells into hemogenic cells and the mechanisms that mediate this process. For more information, visit Dr Moore’s lab page
The van Oudenaarden lab is using a combination of experimental, computational, and theoretical approaches to quantitatively understand decision‐making in single cells with a focus on questions in developmental and stem cell biology. They are particularly interested in how cells use gene networks to make robust decisions even in the presence of significant fluctuations in gene expression. Read more about Dr van Oudenaarden’s research here
Dr. Roger Barker’s main interests are in the neurodegenerative disorders of the nervous system in particular Parkinson's disease and Huntington's disease.  He combines basic research looking at novel therapies (including cell transplants) to treat these conditions with clinically based work on defining the natural history and heterogeneity of both Huntington's disease and Parkinson's disease and is the co-ordinator of the FP7 TRANSEURO project looking at fetal cell grafting in patients with early PD. Visit the Barker Lab for more information
Dr. Sadelain investigates T lymphocytes, hematopoietic stem cells and induced pluripotent stem cells for their potential use in cell-based therapies to treat cancer and genetic disorders. His recent work explores the therapeutic potential of induced pluripotent stem cells, in particular the identification of genomic "safe harbors" for safe and effective genetic engineering.For more information, visit Dr Sadelain’s lab page
Bio coming soon.
Dr Turner’s current research program addresses ethical, legal, and regulatory concerns associated with domestic and international clinics marketing unproven and unlicensed cell-based interventions. In particular, he is investigating the global proliferation of clinics marketing “autologous stem cell treatments” for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis, and many other diseases. Visit Dr Turner’s online profile for more information
Professor Robin Lovell-Badge has had long-standing interests in the biology of stem cells, in how genes work in the context of embryo development, and how decisions of cell fate are made. Major themes of his current work include sex determination, development of the nervous system, and the biology of stem cells within the early embryo, the CNS and the pituitary. He is also very active in both public engagement and policy work, notably around stem cells, genetics, human embryo and animal research, and in ways science is regulated and disseminated.Read about the Dr Lovell-Badge group online for more information
Dr Yamato was originally trained with a background in cell biology and biochemistry, but over the past decades his research interests have been focused on the regeneration of various tissues. He has developed a novel strategy to recover tissue structure and function by using transplantable cell sheets fabricated on temperature-responsive cell culture surfaces. He is currently engaged in various collaborations exploring clinical applications of cell sheets in areas such as ophthalmology, cardiology, gastroenterology, urology, and thoracic surgery.
Dr. Stevens' group is focused on both high quality fundamental science and translation for human health in the regenerative medicine and biosensing fields. Research within her group includes the directed differentiation of stem cells, the design of novel bioactive scaffolds and new approaches towards tissue regeneration. Her group has current research efforts in exploiting specific biomolecular recognition and self-assembly mechanisms to create new dynamic nano-materials, biosensors and drug delivery systems. Recent efforts by the Stevens group in peptide-functionalised nanoparticles for enzyme biosensing have enabled the most sensitive facile enzyme detection to date and have a host of applications across diseases ranging from cancer to global health applications. Visit the Stevens Group online for more information
Research in the Zandstra Laboratory is focused on the generation of functional tissue from adult and pluripotent stem cells. His groups’ quantitative, bioengineering-based approach strives to gain new insight into the fundamental mechanisms that control stem cell fate and to develop robust technologies for the use of stem cells and their derivatives to treat disease. Visit the Zandstra lab online for more information
Professor Greten’s research interests are signal transduction in cells of the tumour microenvironment and translational oncology using suitable mouse models. Read more about Dr Greten’s research on the Georg-Speyer-Haus site
Simón Méndez-Ferrer's group uses the mouse bone marrow as a model system to study multisystem regulatory mechanisms by which the stem cell niche fulfills the complex functions of self-renewal, proliferation, differentiation, and migration and how the deregulation of these mechanisms contributes to disease. Méndez-Ferrer has shown that the cells regulating the movement of hematopoietic stem cells are mesenchymal stem cells, which are precursors to fat and cartilage cells. Méndez -Ferrer’s discovery of this novel function of mesenchymal stem cells is one of the first examples of stem cells for one organ regulating stem cells of another. Visit Dr Mendez-Ferrer’s online profile for more information
Dr. Shi’s research has been focused on immunoregulation. In the recent years, he has been investigating the molecular mechanisms of immunosuppression mediated by mesenchymal stem cells. Through examining the bidirectional interactions between stem cells and immune cells, his research efforts are aimed at elucidating the role of mesenchymal stem cells in modulating tumor immune microenvironment and to design better clinical approaches for proper application of stem cells in clinical settings. Visit Dr Shi’s online profile for more information
At his previous appointment, Dr Underhill’s group described fundamental roles for retinoid signaling in regulating mesenchymal cell differentiation. In 2004, he joined University of British Columbia, and his interests expanded to include investigating how mesenchymal stromal cells support tissue regeneration and tumorigenesis. Read more about Dr Underhill’s research online
Dr. Plath joined the faculty at the University of California Los Angeles in 2006, where she studies mechanisms underlying pluripotency, differentiation, and nuclear reprogramming, with a particular emphasis on chromatin structure and genome organization. Find out more about the Plath Lab online
Professor Xu established the DNA metabolism laboratory in 2001 under the auspices of Max Planck-CAS research group at IBCB, Shanghai, where his team continues to investigate the importance of DNA methylation in stem cells and development. In 2011 his team described a role for Tet DNA dioxygenases in oxidation of 5-methylcytosine to 5-carboxylcytosine and the involvement of a glycosylase –TDG in active demethylation, a critical step for the epigenetic reprogramming of early zygotes and throughout development. Read more about Dr Xu’s research interests online
Dr. Kriegstein’s research focuses on neural stem and progenitor cells in the developing brain and how this knowledge can inform cell-based therapies to treat diseases of the nervous system. Visit Dr Kriegstein’s online profile for more information
Dr Serrano´s laboratory studies the concepts of oncogene-induced senescence, developmental senescence, and the anti-aging activity of tumor suppressors. He has also worked on the role of tumor suppressors in reprogramming to pluripotency, and has recently demonstrated the feasibility of embryonic reprogramming within live adult organisms. Read more about Dr Serrano’s research online
Shinya Yamanaka is Professor and the Director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University and a Senior Investigator at the Gladstone Institute of Cardiovascular Disease in San Francisco. Dr. Yamanaka reported in 2006 that his team succeeded in generating induced pluripotent stem (iPS) cells. For this discovery, Yamanaka received the 2012 Nobel Prize in Physiology or Medicine. Visit Dr Yamanaka’s lab online for more information
Dr. Temple discovered that the embryonic mammalian brain contained a rare, multipotent stem cell that could be extracted and grown in tissue culture to produce both neurons and glia. Her group has continued to make pioneering contributions to the field of neural stem cell research, identifying factors intrinsic to these cells as well as external signaling molecules from the niche that participate in their self-renewal and differentiation. Dr. Temple’s group is focused on studying neural stem cells, and using this knowledge to develop therapies for central nervous system (CNS) disorders. Visit Dr Temple’s online profile for more information
Dr. Albert Edge works on mechanisms of stem cell differentiation and the expression of genes during differentiation of endogenous progenitor cells of the inner ear into cochlear hair cells and neurons. He has discovered cochlear progenitor cells that express Lgr5, a gene also found in the stem cells of the intestine. Wnt signaling stimulates proliferation of Lgr5-expressing cells and converts them into hair cells. He has most recently shown that Notch signaling prevents differentiation of hair cells and that inhibition of Notch after hair cell loss in the adult cochlea can induce hair cell regeneration and a partial recovery of hearing.Visit Dr Edge’s online profile for more information
Dr Dennis Discher is Professor at the University of Pennsylvania, with appointments in Engineering and Applied Science and in the Graduate Groups of Cell & Molecular Biology and Physics. Dr. Discher has coauthored nearly 200 publications, with over 17,000 citations, on topics from matrix mechanobiology of stem cells and nuclei to self-assembling polymers, with papers in Science, Cell, PNAS, and various Nature journals. Read more about Dr Discher’s research online
Trained as a bioengineer, Dr. Swartz uses quantitative approaches in cell biology and physiology, including biotransport and biomechanics, to investigate the role of the lymphatic system in physiology and pathophysiology. She is particularly interested in the role of the lymphatic drainage in maintaining immunological tolerance in homeostasis, and the role of lymphangiogenesis in controlling inflammation as well as inducing pathological tolerance in cancer. Find out more on the Swartz Lab website
When Dr. Okarma served as the President and Chief Executive Officer of Geron Corporation for 12 years, he managed the development of Geron’s human embryonic stem cell program from inception to the initiation of the world’s first FDA-authorized hESC human clinical trial in spinal cord injury – a milestone in the history of biotechnology. Visit Dr Okarma’s company website for more information
Dr Rudnicki's laboratory works to understand the molecular mechanisms that regulate the determination, proliferation, and differentiation of stem cells during embryonic development and during tissue regeneration. They have worked extensively to understand the molecular mechanisms that regulate the function of satellite cells in skeletal muscle. Visit the Rudnicki Lab website for more information
Bio coming soon.
Dr Michael Sieweke directs the group of stem cell and macrophage biology at the Centre d’Immunologie de Marseille-Luminy (CIML) in Marseille, France. He has been interested in differentiation and growth control throughout his career, with a focus on transcription factors in hematopoietic stem cells and macrophages. He is studying the molecular mechanisms governing cellular identity and self-renewal in stem cells and differentiated cells. Find out more about Dr Sieweke’s research on his Lab website
Dr Orkin completed his pediatric hematology/oncology training at Children's Hospital and the Dana Farber Cancer Institute (DFCI), and trained in the laboratory of Philip Leder at NIH. His research focuses on intersections of transcriptional control with stem cell biology, hematopoiesis, and cancer. Visit Dr Orkin’s online profile for more information
Dr Spalding is currently an Assistant Professor in the Department of Cell and Molecular Biology at the Karolinska Institute. Her primary research field is regenerative cell biology, with a focus on cell turnover in human brain and fat tissue. Her research group looks at the turnover and maintenance of adipose tissue (cells and lipid) in humans, in health and pathology. Visit Dr Spalding’s online profile for more information
Dr Rong Li’s work employs an interdisciplinary approach combining biochemistry, genetics, quantitative imaging and fluorescence spectroscopy, mathematical and computational modeling, genomics and proteomics. Current research areas in her laboratory include cell polarity, asymmetric cell division, actin-based motility, chromosome instability and copy number variation, and evolutionary dynamics of cellular systems. Read more about Dr Rong Li’s research online
Dr. Roeland Nusse’s laboratory is interested in the growth, development and integrity of animal tissues. They study multiple different organs, trying to identify common principles, and they extend these investigations to cancer and injury repair. Visit the Nusse Laboratory online for more information about Dr Nusse’s research
Dr Sasaki’s research focuses on the regulation of the mammalian epigenome in germ cells and early embryos. He is particularly interested in DNA methylation and small RNA-based mechanisms and studies genomic imprinting as a model system. He is the former president of the Japanese Society for Epigenetics and currently served as a board member of the Japan Society of Human Genetics, a counselor of Genetics Society of Japan, a member of the ISSC of the International Human Epigenome Consortium. View Dr Sasaki’s online profile for more information
Dr. Sander's research focuses on understanding the molecular mechanisms that underlie the formation, regeneration and proper function of endocrine cells in the pancreas. Her work has revealed important transcriptional mechanisms of pancreatic beta cell formation. Her laboratory has recently published the first genome-wide map of the transcriptional and epigenetic changes that occur during progression of human embryonic stem cells toward terminally-differentiated pancreatic endocrine cells.Learn more on the Sander Lab website
Dr Maria Cristina Nostro received her Ph.D. from The University of Manchester in 2004. The same year, she joined Dr. Gordon Keller’s laboratory, where she used embryonic stem cells to investigate the molecular mechanisms regulating mesoderm and endoderm lineage commitment. In 2012, she started her independent career at the TGRI. The work in her laboratory is focused on the generation of pancreatic beta cells from human embryonic and induced pluripotent stem cells.Read more about Dr Nostro’s research online
Dr. Parada laboratory uses genetic mouse models to study human disease including nervous system cancers, Neurofibromatosis, and autism. Dr. Parada obtained a B.S. from the University of Wisconsin and a Ph.D. in Biology from MIT, identifying oncogenes in human cancer. Visit the Luis Parada Lab for more information
His research focuses on several areas of interest, which include 1) Functional studies of genes belonging to families with known roles in vessel formation; 2) Development of sophisticated genetic manipulation tools in the mouse model; 3) Applying genetics to cancer research; 4) Derivation, differentiation and genetic modification of both mouse and human Embryonic Stem cells; 5) Reprogramming of somatic cells to pluripotent stem cells. Visit the Nagy Lab for more information